Loading...

FITC Streptavidin FITC Streptavidin

Pricing & Availability
Regulatory Status
RUO
Other Names
Streptavidin-Fluorescein Isothiocyanate, SAv-FITC
Ave. Rating
Submit a Review
Product Citations
publications
SAV_FITC_082808.jpg
C57BL/6 splenocytes stained with 145-2C11 biotin, followed by Sav-FITC
  • SAV_FITC_082808.jpg
    C57BL/6 splenocytes stained with 145-2C11 biotin, followed by Sav-FITC
See FITC spectral data
Cat # Size Price Quantity Check Availability Save
405201 100 µg NOK347
Check Availability


Need larger quantities of this item?
Request Bulk Quote
405202 500 µg NOK974
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

Streptavidin binds to biotin with high affinity. Streptavidin-fluorescein isothiocyanate (FITC) is useful for detecting biotinylated antibodies. The excitation of FITC by 488 nm laser light induces a light emission maximum of 520 nm.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Human, Mouse, Rat, All Species
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Storage & Handling
The Streptavidin-FITC solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested

ICFC - Verified
Recommended Usage

Each lot of this Streptavidin-FITC is quality control tested by immunofluorescent staining with flow cytometric analysis. The concentration provided is based upon molecular mass of streptavidin independent of any additional molecular mass that might be added by the FITC conjugation. For immunofluorescent staining, the recommended use of this reagent is ≤ 0.25 µg per 106 cells in 100 µl staining volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Blue Laser (488 nm)
Application Notes

Streptavidin-FITC is useful as a second step reagent for indirect immunofluorescent staining, in conjunction with biotinylated primary antibodies. The average molecular weight of Streptavidin-FITC is 60 kD and Streptavidin alone is 52 kD.

Application References
  1. Schmutz S, et al. 2009. J. Immunol. 183:2217. PubMed
  2. Cho HY, et al. 2009. Immunol Lett. 127:39. PubMed
  3. de Wispelaere D, et al. 2012. J. Virol. 86:7072. PubMed
  4. Fukuoka A, et al. 2013. Int Immunol. PubMed
  5. Giltiay NV, et al. 2013. J Exp Med. 25:373. PubMed
  6. Lee JH, et al. 2014. J Rheumatol. 41:2425. PubMed
Product Citations
  1. Du J, et al. 2022. Sci Immunol. 7:eabo5407. PubMed
  2. Pymm P, et al. 2022. iScience. 25:105259. PubMed
  3. Yu H, et al. 2023. Nat Commun. 14:1058. PubMed
  4. Luo Y, et al. 2023. Cell Discov. 9:40. PubMed
  5. Chen K, et al. 2023. Gut Pathog. 15:28. PubMed
  6. Kemble S, et al. 2022. Blood Adv. 6:2932. PubMed
  7. Glass MC, et al. 2022. Cell Rep. 39:110728. PubMed
  8. Lorenzo-Martín LF, et al. 2022. Oncogene. 41:3341. PubMed
  9. Lin G, et al. 2022. Int J Immunopathol Pharmacol. 36:3946320221117933. PubMed
  10. Parnigoni A, et al. 2022. Matrix Biol. 109:140. PubMed
  11. Georgiadis C, et al. 2021. Leukemia. . PubMed
  12. Larsen SB, et al. 2021. Cell Stem Cell. 28:1758. PubMed
  13. Krishack PA, et al. 2019. JCI Insight. 4:6. PubMed
  14. Sasaki N, Itakura Y, Toyoda M 2017. Stem Cell Res Ther. 10.1186/s13287-017-0534-1. PubMed
  15. Suarez-Calvet X, et al. 2021. FASEB J. 35:e21819. PubMed
  16. Zaitouna AJ, et al. 2020. Bio Protoc. 10:e3655. PubMed
  17. Yang M 2012. J Virol. 86:7072. PubMed
  18. Pan H, et al. 2020. Mol Psychiatry. . PubMed
  19. Wang Y, et al. 2021. Nat Commun. 12:2343. PubMed
  20. Sánchez-Salguero E, et al. 2021. Front Immunol. 12:712130. PubMed
  21. Hu Y, et al. 2022. Nat Commun. 13:5313. PubMed
  22. Li S, et al. 2016. PLoS One. 11: 0163893. PubMed
  23. Lee J, et al. 2014. J Rheumatol. 41:2425. PubMed
  24. Hurrell BP, et al. 2019. Cell Rep. 29:4509. PubMed
  25. Vigeland C, et al. 2016. PLoS One. 11: 0163288. PubMed
  26. Morimoto A, et al. 2021. Nat Commun. 12:2136. PubMed
  27. Noviski M, et al. 2018. Elife. 7:e35074. PubMed
  28. Zhang Y, et al. 2019. JCI Insight. 4:2. PubMed
  29. Yan R, et al. 2021. Cell Death Dis. 12:955. PubMed
  30. Galle-Treger L, et al. 2016. Nat Commun. 7:13202. PubMed
  31. Schmutz S, et al. 2009. J Immunol. 183:2217. PubMed
  32. Delacher M, et al. 2020. Immunity. 52:295. PubMed
  33. Cheng LS, et al. 2022. J Transl Med. 20:415. PubMed
  34. Shafiei-Jahani P, et al. 2021. Nat Commun. 12:2526. PubMed
  35. Matt P, et al. 2015. PLoS One. 10: 0137474. PubMed
  36. Galle-Treger L, et al. 2019. Nat Commun. 10:713. PubMed
  37. Bülow JM, et al. 2022. Front Endocrinol (Lausanne). 13:1016057. PubMed
  38. Oda Y, et al. 2021. Sci Adv. 7:eabj6895. PubMed
  39. Li X, et al. 2021. Oncol Lett. 22:788. PubMed
  40. Cho H, et al. 2009. Immunol Lett. 127:39. PubMed
  41. Buffolo M, et al. 2019. Cell Rep. 29:270. PubMed
  42. Wang Y, et al. 2022. Front Immunol. 13:847581. PubMed
  43. Hensel JA, et al. 2019. Mol Ther Oncolytics. 12:41. PubMed
  44. Lin Y, et al. 2012. PLoS One. 7:e30507. PubMed
  45. Fukuoka A, et al. 2013. Int Immunol. 25:373. PubMed
  46. Giltiay N, et al. 2013. J Exp Med. 210:2773. PubMed
  47. Mchedlidze T, et al. 2016. Mucosal Immunol. 10.1038/mi.2016.20. PubMed
  48. SL C, et al. 2016. JCI Insight. 1: 83116. PubMed
  49. Mödinger Y, et al. 2018. J Cell Mol Med. 22:6002. PubMed
  50. Hamester F, et al. 2022. Cells. 11:. PubMed
  51. Laurin M, et al. 2019. Elife. 8. PubMed
  52. Sturmlechner I, et al. 2021. Science. 374:eabb3420. PubMed
  53. Geng S, et al. 2016. Nat Commun. 7:13436. PubMed
  54. Zhu Z, et al. 2017. Int J Biochem Cell Biol. 10.1016/j.biocel.2017.04.003. PubMed
  55. Lindsay RS, et al. 2021. J Exp Med. 218:. PubMed
  56. Vogiatzi A, et al. 2021. Mol Cell Biol. 41:e0014921. PubMed
  57. Du J, et al. 2022. Sci Immunol. 7:eabo5407. PubMed
  58. Pymm P, et al. 2022. iScience. 25:105259. PubMed
  59. Yu H, et al. 2023. Nat Commun. 14:1058. PubMed
  60. Luo Y, et al. 2023. Cell Discov. 9:40. PubMed
  61. Chen K, et al. 2023. Gut Pathog. 15:28. PubMed
  62. Kemble S, et al. 2022. Blood Adv. 6:2932. PubMed
  63. Glass MC, et al. 2022. Cell Rep. 39:110728. PubMed
  64. Lorenzo-Martín LF, et al. 2022. Oncogene. 41:3341. PubMed
  65. Lin G, et al. 2022. Int J Immunopathol Pharmacol. 36:3946320221117933. PubMed
  66. Parnigoni A, et al. 2022. Matrix Biol. 109:140. PubMed
  67. Georgiadis C, et al. 2021. Leukemia. . PubMed
  68. Larsen SB, et al. 2021. Cell Stem Cell. 28:1758. PubMed
  69. Krishack PA, et al. 2019. JCI Insight. 4:6. PubMed
  70. Sasaki N, Itakura Y, Toyoda M 2017. Stem Cell Res Ther. 10.1186/s13287-017-0534-1. PubMed
  71. Suarez-Calvet X, et al. 2021. FASEB J. 35:e21819. PubMed
  72. Zaitouna AJ, et al. 2020. Bio Protoc. 10:e3655. PubMed
  73. Yang M 2012. J Virol. 86:7072. PubMed
  74. Pan H, et al. 2020. Mol Psychiatry. . PubMed
  75. Wang Y, et al. 2021. Nat Commun. 12:2343. PubMed
  76. Sánchez-Salguero E, et al. 2021. Front Immunol. 12:712130. PubMed
  77. Hu Y, et al. 2022. Nat Commun. 13:5313. PubMed
  78. Li S, et al. 2016. PLoS One. 11: 0163893. PubMed
  79. Lee J, et al. 2014. J Rheumatol. 41:2425. PubMed
  80. Hurrell BP, et al. 2019. Cell Rep. 29:4509. PubMed
  81. Vigeland C, et al. 2016. PLoS One. 11: 0163288. PubMed
  82. Morimoto A, et al. 2021. Nat Commun. 12:2136. PubMed
  83. Noviski M, et al. 2018. Elife. 7:e35074. PubMed
  84. Zhang Y, et al. 2019. JCI Insight. 4:2. PubMed
  85. Yan R, et al. 2021. Cell Death Dis. 12:955. PubMed
  86. Galle-Treger L, et al. 2016. Nat Commun. 7:13202. PubMed
  87. Schmutz S, et al. 2009. J Immunol. 183:2217. PubMed
  88. Delacher M, et al. 2020. Immunity. 52:295. PubMed
  89. Cheng LS, et al. 2022. J Transl Med. 20:415. PubMed
  90. Shafiei-Jahani P, et al. 2021. Nat Commun. 12:2526. PubMed
  91. Matt P, et al. 2015. PLoS One. 10: 0137474. PubMed
  92. Galle-Treger L, et al. 2019. Nat Commun. 10:713. PubMed
  93. Bülow JM, et al. 2022. Front Endocrinol (Lausanne). 13:1016057. PubMed
  94. Oda Y, et al. 2021. Sci Adv. 7:eabj6895. PubMed
  95. Li X, et al. 2021. Oncol Lett. 22:788. PubMed
  96. Cho H, et al. 2009. Immunol Lett. 127:39. PubMed
  97. Buffolo M, et al. 2019. Cell Rep. 29:270. PubMed
  98. Wang Y, et al. 2022. Front Immunol. 13:847581. PubMed
  99. Hensel JA, et al. 2019. Mol Ther Oncolytics. 12:41. PubMed
  100. Lin Y, et al. 2012. PLoS One. 7:e30507. PubMed
  101. Fukuoka A, et al. 2013. Int Immunol. 25:373. PubMed
  102. Giltiay N, et al. 2013. J Exp Med. 210:2773. PubMed
  103. Mchedlidze T, et al. 2016. Mucosal Immunol. 10.1038/mi.2016.20. PubMed
  104. SL C, et al. 2016. JCI Insight. 1: 83116. PubMed
  105. Mödinger Y, et al. 2018. J Cell Mol Med. 22:6002. PubMed
  106. Hamester F, et al. 2022. Cells. 11:. PubMed
  107. Laurin M, et al. 2019. Elife. 8. PubMed
  108. Sturmlechner I, et al. 2021. Science. 374:eabb3420. PubMed
  109. Geng S, et al. 2016. Nat Commun. 7:13436. PubMed
  110. Zhu Z, et al. 2017. Int J Biochem Cell Biol. 10.1016/j.biocel.2017.04.003. PubMed
  111. Lindsay RS, et al. 2021. J Exp Med. 218:. PubMed
  112. Vogiatzi A, et al. 2021. Mol Cell Biol. 41:e0014921. PubMed

Related FAQs

There are no FAQs for this product.
Go To Top Version: 5    Revision Date: 06.17.2019

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

Pricing & Availability
Regulatory Status
RUO
Other Names
Streptavidin-Fluorescein Isothiocyanate, SAv-FITC
Ave. Rating
Submit a Review
Product Citations
publications
SAV_FITC_082808.jpg
C57BL/6 splenocytes stained with 145-2C11 biotin, followed by Sav-FITC
  • SAV_FITC_082808.jpg
    C57BL/6 splenocytes stained with 145-2C11 biotin, followed by Sav-FITC
See FITC spectral data
Cat # Size Price Quantity Check Availability Save
405201 100 µg NOK347
Check Availability


Need larger quantities of this item?
Request Bulk Quote
405202 500 µg NOK974
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

Streptavidin binds to biotin with high affinity. Streptavidin-fluorescein isothiocyanate (FITC) is useful for detecting biotinylated antibodies. The excitation of FITC by 488 nm laser light induces a light emission maximum of 520 nm.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Human, Mouse, Rat, All Species
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Storage & Handling
The Streptavidin-FITC solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested

ICFC - Verified
Recommended Usage

Each lot of this Streptavidin-FITC is quality control tested by immunofluorescent staining with flow cytometric analysis. The concentration provided is based upon molecular mass of streptavidin independent of any additional molecular mass that might be added by the FITC conjugation. For immunofluorescent staining, the recommended use of this reagent is ≤ 0.25 µg per 106 cells in 100 µl staining volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Blue Laser (488 nm)
Application Notes

Streptavidin-FITC is useful as a second step reagent for indirect immunofluorescent staining, in conjunction with biotinylated primary antibodies. The average molecular weight of Streptavidin-FITC is 60 kD and Streptavidin alone is 52 kD.

Application References
  1. Schmutz S, et al. 2009. J. Immunol. 183:2217. PubMed
  2. Cho HY, et al. 2009. Immunol Lett. 127:39. PubMed
  3. de Wispelaere D, et al. 2012. J. Virol. 86:7072. PubMed
  4. Fukuoka A, et al. 2013. Int Immunol. PubMed
  5. Giltiay NV, et al. 2013. J Exp Med. 25:373. PubMed
  6. Lee JH, et al. 2014. J Rheumatol. 41:2425. PubMed
Product Citations
  1. Du J, et al. 2022. Sci Immunol. 7:eabo5407. PubMed
  2. Pymm P, et al. 2022. iScience. 25:105259. PubMed
  3. Yu H, et al. 2023. Nat Commun. 14:1058. PubMed
  4. Luo Y, et al. 2023. Cell Discov. 9:40. PubMed
  5. Chen K, et al. 2023. Gut Pathog. 15:28. PubMed
  6. Kemble S, et al. 2022. Blood Adv. 6:2932. PubMed
  7. Glass MC, et al. 2022. Cell Rep. 39:110728. PubMed
  8. Lorenzo-Martín LF, et al. 2022. Oncogene. 41:3341. PubMed
  9. Lin G, et al. 2022. Int J Immunopathol Pharmacol. 36:3946320221117933. PubMed
  10. Parnigoni A, et al. 2022. Matrix Biol. 109:140. PubMed
  11. Georgiadis C, et al. 2021. Leukemia. . PubMed
  12. Larsen SB, et al. 2021. Cell Stem Cell. 28:1758. PubMed
  13. Krishack PA, et al. 2019. JCI Insight. 4:6. PubMed
  14. Sasaki N, Itakura Y, Toyoda M 2017. Stem Cell Res Ther. 10.1186/s13287-017-0534-1. PubMed
  15. Suarez-Calvet X, et al. 2021. FASEB J. 35:e21819. PubMed
  16. Zaitouna AJ, et al. 2020. Bio Protoc. 10:e3655. PubMed
  17. Yang M 2012. J Virol. 86:7072. PubMed
  18. Pan H, et al. 2020. Mol Psychiatry. . PubMed
  19. Wang Y, et al. 2021. Nat Commun. 12:2343. PubMed
  20. Sánchez-Salguero E, et al. 2021. Front Immunol. 12:712130. PubMed
  21. Hu Y, et al. 2022. Nat Commun. 13:5313. PubMed
  22. Li S, et al. 2016. PLoS One. 11: 0163893. PubMed
  23. Lee J, et al. 2014. J Rheumatol. 41:2425. PubMed
  24. Hurrell BP, et al. 2019. Cell Rep. 29:4509. PubMed
  25. Vigeland C, et al. 2016. PLoS One. 11: 0163288. PubMed
  26. Morimoto A, et al. 2021. Nat Commun. 12:2136. PubMed
  27. Noviski M, et al. 2018. Elife. 7:e35074. PubMed
  28. Zhang Y, et al. 2019. JCI Insight. 4:2. PubMed
  29. Yan R, et al. 2021. Cell Death Dis. 12:955. PubMed
  30. Galle-Treger L, et al. 2016. Nat Commun. 7:13202. PubMed
  31. Schmutz S, et al. 2009. J Immunol. 183:2217. PubMed
  32. Delacher M, et al. 2020. Immunity. 52:295. PubMed
  33. Cheng LS, et al. 2022. J Transl Med. 20:415. PubMed
  34. Shafiei-Jahani P, et al. 2021. Nat Commun. 12:2526. PubMed
  35. Matt P, et al. 2015. PLoS One. 10: 0137474. PubMed
  36. Galle-Treger L, et al. 2019. Nat Commun. 10:713. PubMed
  37. Bülow JM, et al. 2022. Front Endocrinol (Lausanne). 13:1016057. PubMed
  38. Oda Y, et al. 2021. Sci Adv. 7:eabj6895. PubMed
  39. Li X, et al. 2021. Oncol Lett. 22:788. PubMed
  40. Cho H, et al. 2009. Immunol Lett. 127:39. PubMed
  41. Buffolo M, et al. 2019. Cell Rep. 29:270. PubMed
  42. Wang Y, et al. 2022. Front Immunol. 13:847581. PubMed
  43. Hensel JA, et al. 2019. Mol Ther Oncolytics. 12:41. PubMed
  44. Lin Y, et al. 2012. PLoS One. 7:e30507. PubMed
  45. Fukuoka A, et al. 2013. Int Immunol. 25:373. PubMed
  46. Giltiay N, et al. 2013. J Exp Med. 210:2773. PubMed
  47. Mchedlidze T, et al. 2016. Mucosal Immunol. 10.1038/mi.2016.20. PubMed
  48. SL C, et al. 2016. JCI Insight. 1: 83116. PubMed
  49. Mödinger Y, et al. 2018. J Cell Mol Med. 22:6002. PubMed
  50. Hamester F, et al. 2022. Cells. 11:. PubMed
  51. Laurin M, et al. 2019. Elife. 8. PubMed
  52. Sturmlechner I, et al. 2021. Science. 374:eabb3420. PubMed
  53. Geng S, et al. 2016. Nat Commun. 7:13436. PubMed
  54. Zhu Z, et al. 2017. Int J Biochem Cell Biol. 10.1016/j.biocel.2017.04.003. PubMed
  55. Lindsay RS, et al. 2021. J Exp Med. 218:. PubMed
  56. Vogiatzi A, et al. 2021. Mol Cell Biol. 41:e0014921. PubMed
  57. Du J, et al. 2022. Sci Immunol. 7:eabo5407. PubMed
  58. Pymm P, et al. 2022. iScience. 25:105259. PubMed
  59. Yu H, et al. 2023. Nat Commun. 14:1058. PubMed
  60. Luo Y, et al. 2023. Cell Discov. 9:40. PubMed
  61. Chen K, et al. 2023. Gut Pathog. 15:28. PubMed
  62. Kemble S, et al. 2022. Blood Adv. 6:2932. PubMed
  63. Glass MC, et al. 2022. Cell Rep. 39:110728. PubMed
  64. Lorenzo-Martín LF, et al. 2022. Oncogene. 41:3341. PubMed
  65. Lin G, et al. 2022. Int J Immunopathol Pharmacol. 36:3946320221117933. PubMed
  66. Parnigoni A, et al. 2022. Matrix Biol. 109:140. PubMed
  67. Georgiadis C, et al. 2021. Leukemia. . PubMed
  68. Larsen SB, et al. 2021. Cell Stem Cell. 28:1758. PubMed
  69. Krishack PA, et al. 2019. JCI Insight. 4:6. PubMed
  70. Sasaki N, Itakura Y, Toyoda M 2017. Stem Cell Res Ther. 10.1186/s13287-017-0534-1. PubMed
  71. Suarez-Calvet X, et al. 2021. FASEB J. 35:e21819. PubMed
  72. Zaitouna AJ, et al. 2020. Bio Protoc. 10:e3655. PubMed
  73. Yang M 2012. J Virol. 86:7072. PubMed
  74. Pan H, et al. 2020. Mol Psychiatry. . PubMed
  75. Wang Y, et al. 2021. Nat Commun. 12:2343. PubMed
  76. Sánchez-Salguero E, et al. 2021. Front Immunol. 12:712130. PubMed
  77. Hu Y, et al. 2022. Nat Commun. 13:5313. PubMed
  78. Li S, et al. 2016. PLoS One. 11: 0163893. PubMed
  79. Lee J, et al. 2014. J Rheumatol. 41:2425. PubMed
  80. Hurrell BP, et al. 2019. Cell Rep. 29:4509. PubMed
  81. Vigeland C, et al. 2016. PLoS One. 11: 0163288. PubMed
  82. Morimoto A, et al. 2021. Nat Commun. 12:2136. PubMed
  83. Noviski M, et al. 2018. Elife. 7:e35074. PubMed
  84. Zhang Y, et al. 2019. JCI Insight. 4:2. PubMed
  85. Yan R, et al. 2021. Cell Death Dis. 12:955. PubMed
  86. Galle-Treger L, et al. 2016. Nat Commun. 7:13202. PubMed
  87. Schmutz S, et al. 2009. J Immunol. 183:2217. PubMed
  88. Delacher M, et al. 2020. Immunity. 52:295. PubMed
  89. Cheng LS, et al. 2022. J Transl Med. 20:415. PubMed
  90. Shafiei-Jahani P, et al. 2021. Nat Commun. 12:2526. PubMed
  91. Matt P, et al. 2015. PLoS One. 10: 0137474. PubMed
  92. Galle-Treger L, et al. 2019. Nat Commun. 10:713. PubMed
  93. Bülow JM, et al. 2022. Front Endocrinol (Lausanne). 13:1016057. PubMed
  94. Oda Y, et al. 2021. Sci Adv. 7:eabj6895. PubMed
  95. Li X, et al. 2021. Oncol Lett. 22:788. PubMed
  96. Cho H, et al. 2009. Immunol Lett. 127:39. PubMed
  97. Buffolo M, et al. 2019. Cell Rep. 29:270. PubMed
  98. Wang Y, et al. 2022. Front Immunol. 13:847581. PubMed
  99. Hensel JA, et al. 2019. Mol Ther Oncolytics. 12:41. PubMed
  100. Lin Y, et al. 2012. PLoS One. 7:e30507. PubMed
  101. Fukuoka A, et al. 2013. Int Immunol. 25:373. PubMed
  102. Giltiay N, et al. 2013. J Exp Med. 210:2773. PubMed
  103. Mchedlidze T, et al. 2016. Mucosal Immunol. 10.1038/mi.2016.20. PubMed
  104. SL C, et al. 2016. JCI Insight. 1: 83116. PubMed
  105. Mödinger Y, et al. 2018. J Cell Mol Med. 22:6002. PubMed
  106. Hamester F, et al. 2022. Cells. 11:. PubMed
  107. Laurin M, et al. 2019. Elife. 8. PubMed
  108. Sturmlechner I, et al. 2021. Science. 374:eabb3420. PubMed
  109. Geng S, et al. 2016. Nat Commun. 7:13436. PubMed
  110. Zhu Z, et al. 2017. Int J Biochem Cell Biol. 10.1016/j.biocel.2017.04.003. PubMed
  111. Lindsay RS, et al. 2021. J Exp Med. 218:. PubMed
  112. Vogiatzi A, et al. 2021. Mol Cell Biol. 41:e0014921. PubMed
Go To Top Version: 5    Revision Date: 06.17.2019

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account